Literature DB >> 31586304

Intestinal thrombotic microangiopathy: a distinct entity in the spectrum of graft-versus-host disease.

Eleni Gavriilaki1, Ioanna Sakellari2, Ioanna Karafoulidou3, Nikoleta Pasteli3, Ioannis Batsis2, Despina Mallouri2, Andriana Lazaridou2, Michalis Iskas2, Anna Vardi2, Apostolia Papalexandri2, Aliki Tsompanakou2, Styliani Papaemmanouil3, Anastasios Ilias4, Achilles Anagnostopoulos2.   

Abstract

Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT) with multisystem involvement. Cases of TMA in the intestinal vasculature (intestinal TMA/iTMA) have been reported. We hypothesized that iTMA is a distinct entity from TA-TMA. To test this hypothesis, we prospectively recruited allo-HCT recipients with an indication for endoscopy. Among 20 patients, histological features of iTMA, including loss of glands, total denudation of mucosa, apoptosis and detachment of endothelial cells, mucosal hemorrhage, intraluminal fibrin and microthrombi were found in six. Only 2/6 were classified as GVHD/TA-TMA, while the other 4 as GVHD/no TA-TMA. Gastro-intestinal symptoms were similar between the patients with or without iTMA. With a median follow-up of 11.1 (2.1-67.5) months, 1-year overall survival was 22.2% for iTMA, 55% for GVHD and 60% for TA-TMA. On multivariate analysis, independent unfavorable predictors of OS were iTMA (p = 0.048), HLA mismatched donors (p = 0.008) and gastro-intestinal bleeding (p = 0.021). In conclusion, iTMA emerges as a novel distinct entity in patients with GVHD and/or TA-TMA. Distinct histological features may be useful in differential diagnosis of these severe HCT complications. The higher mortality rates of iTMA than TA-TMA highlight the need for further investigation of this condition.

Entities:  

Keywords:  Endoscopy; Graft-versus-host disease; Hematopoietic cell transplantation; Intestinal; Thrombotic microangiopathy

Mesh:

Year:  2019        PMID: 31586304     DOI: 10.1007/s12185-019-02750-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  14 in total

1.  Diagnosis of intestinal graft-versus-host disease and thrombotic microangiopathy after allogeneic stem cell transplantation.

Authors:  Minami Yamada-Fujiwara; Koichi Miyamura; Tohru Fujiwara; Yasuo Tohmiya; Katsuya Endo; Yasushi Onishi; Kenichi Ishizawa; Junichi Kameoka; Masafumi Ito; Hideo Harigae
Journal:  Tohoku J Exp Med       Date:  2012-05       Impact factor: 1.848

2.  Late-onset intestinal perforation in the setting of posttransplantation microangiopathy: a case report.

Authors:  O S Aljitawi; L Rodriguez; R Madan; S Ganguly; S Abhyankar; J P McGuirk
Journal:  Transplant Proc       Date:  2010-11       Impact factor: 1.066

3.  Intestinal perforation secondary to haematopoietic stem cell transplant associated thrombotic microangiopathy.

Authors:  Saman Hewamana; Belinda Austen; James Murray; Sarah Johnson; Keith Wilson
Journal:  Eur J Haematol       Date:  2009-04-13       Impact factor: 2.997

4.  Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation.

Authors:  Javier El-Bietar; Mikako Warren; Christopher Dandoy; Kasiani C Myers; Adam Lane; Gregory Wallace; Stella M Davies; Sonata Jodele
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-04       Impact factor: 5.742

5.  Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases.

Authors:  Ioanna Sakellari; Eleni Gavriilaki; Zoi Boussiou; Ioannis Batsis; Despoina Mallouri; V Constantinou; Kaloyannidis Kaloyannidis; Evangelia Yannaki; Gerasimos Bamihas; Achilles Anagnostopoulos
Journal:  Hematol Oncol       Date:  2016-09-19       Impact factor: 5.271

6.  Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD.

Authors:  Sarah A Wall; Qiuhong Zhao; Martha Yearsley; Luke Blower; Akwasi Agyeman; Parvathi Ranganathan; Shangbin Yang; Haiwa Wu; Matthew Bostic; Samantha Jaglowski; Jonathan E Brammer; Basem William; Hannah Choe; Alice S Mims; Sam Penza; Yvonne Efebera; Steven Devine; Spero Cataland; Stella M Davies; Sumithira Vasu
Journal:  Blood Adv       Date:  2018-10-23

7.  Intestinal ischemia after allogeneic stem cell transplantation: a report of four cases.

Authors:  L Prochaska; J Vacek; R Madan; S Abhyankar; S Ganguly; J P McGuirk; T L Lin; O S Aljitawi
Journal:  Transplant Proc       Date:  2014-06       Impact factor: 1.066

8.  Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease.

Authors:  T Nishida; M Hamaguchi; N Hirabayashi; M Haneda; S Terakura; Y Atsuta; S Imagama; T Kanie; M Murata; H Taji; R Suzuki; Y Morishita; Y Kodera
Journal:  Bone Marrow Transplant       Date:  2004-06       Impact factor: 5.483

Review 9.  Transplant-associated thrombotic microangiopathy: opening Pandora's box.

Authors:  E Gavriilaki; I Sakellari; A Anagnostopoulos; R A Brodsky
Journal:  Bone Marrow Transplant       Date:  2017-03-13       Impact factor: 5.483

10.  Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation.

Authors:  Eleni Gavriilaki; Ioanna Sakellari; Ioannis Batsis; Despina Mallouri; Zoi Bousiou; Anna Vardi; Evangelia Yannaki; Varnavas Constantinou; Aliki Tsompanakou; Chrysanthi Vadikoliou; Panayotis Kaloyannidis; Gerasimos Bamihas; Achilles Anagnostopoulos
Journal:  Clin Transplant       Date:  2018-08-20       Impact factor: 2.863

View more
  7 in total

1.  Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.

Authors:  Sonata Jodele; Christopher E Dandoy; Adam Lane; Benjamin L Laskin; Ashley Teusink-Cross; Kasiani C Myers; Gregory Wallace; Adam Nelson; Jack Bleesing; Ranjit S Chima; Russel Hirsch; Thomas D Ryan; Stefanie Benoit; Kana Mizuno; Mikako Warren; Stella M Davies
Journal:  Blood       Date:  2020-03-26       Impact factor: 22.113

2.  Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation.

Authors:  Eleni Gavriilaki; Ioanna Sakellari; Panagiota Anyfanti; Ioannis Batsis; Anna Vardi; Zoi Bousiou; Antonios Lazaridis; Barbara Nikolaidou; Ippokratis Zarifis; Marianna Masmanidou; Efthalia Yiannaki; Dimitra Markala; Achilles Anagnostopoulos; Stella Douma; Eugenia Gkaliagkousi
Journal:  Int J Mol Sci       Date:  2020-12-21       Impact factor: 5.923

3.  [Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy (2021)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-03-14

Review 4.  Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis.

Authors:  Joanna A Young; Christopher R Pallas; Mary Ann Knovich
Journal:  Bone Marrow Transplant       Date:  2021-04-19       Impact factor: 5.174

Review 5.  Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy.

Authors:  Eleni Gavriilaki; Vincent T Ho; Wilhelm Schwaeble; Thomas Dudler; Mohamed Daha; Teizo Fujita; Sonata Jodele
Journal:  Exp Hematol Oncol       Date:  2021-12-19

Review 6.  The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD).

Authors:  Christos Demosthenous; Ioanna Sakellari; Vassiliki Douka; Penelope Georgia Papayanni; Achilles Anagnostopoulos; Eleni Gavriilaki
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

Review 7.  Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis.

Authors:  Vincenzo Cardinale; Gabriele Capurso; Gianluca Ianiro; Antonio Gasbarrini; Paolo Giorgio Arcidiacono; Domenico Alvaro
Journal:  Dig Liver Dis       Date:  2020-09-16       Impact factor: 4.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.